Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Lytix Biopharma AS ( (DE:6BG) ) has provided an update.
Lytix Biopharma has strengthened its financial position by completing a subsequent offering that raised NOK 16.3 million in gross proceeds and resulted in the issuance of 1,811,803 new shares. Following registration of the capital increase in the Norwegian Register of Business Enterprises, the company’s share capital now totals NOK 7,690,000.50, divided into 76,900,005 shares, with the new shares expected to be recorded in the VPS by 25 February 2026.
The completion and registration of this share issue supports Lytix Biopharma’s ability to fund its clinical development pipeline and reinforces its status as a listed company on Euronext Growth Oslo. The enlarged capital base may provide greater flexibility for ongoing and future cancer immunotherapy programs, which is relevant for investors monitoring the company’s progress and financing capacity.
More about Lytix Biopharma AS
Lytix Biopharma AS is a clinical-stage biotechnology company based in Oslo, Norway, developing novel cancer immunotherapies built on host-defense peptide-derived molecules. Its lead product, LTX-315, is a first-in-class oncolytic molecule designed to boost anti-cancer immunity, supported by a pipeline targeting multiple cancer indications as both mono- and combination therapies.
Average Trading Volume: 60,236
Current Market Cap: NOK690.8M
For an in-depth examination of 6BG stock, go to TipRanks’ Overview page.